Windtree Therapeutics Inc. has entered into a new financing arrangement by issuing an aggregate principal amount of $1.6 million in senior convertible promissory notes due 2026 to institutional investors. The notes were issued in connection with the termination and settlement of prior agreements related to a real estate transaction involving its subsidiary, WINT Real Estate, LLC, and Way Maker Growth Fund, LLC. The notes accrue interest at 10% per annum and mature on October 9, 2026. They are junior to the company's June 2025 convertible promissory note issued to DFU, LLC, which has priority over other company indebtedness. The notes are convertible into Windtree's common stock at the holders' option, with a beneficial ownership limitation, and are subject to prepayment terms in connection with any qualified equity financing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-031178), on October 16, 2025, and is solely responsible for the information contained therein.
Comments